Assignee
KINIKSA PHARMACEUTICALS LTD
US·9 granted patents·15 pending applications·12 citations·filing 2014–2024
Top patents by PatentIndex Score
24 records- 0189US2025230250A1Oncostatin m receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 0288US9593163B2Oncostatin M receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2016·Granted Mar 14, 2017·5 cites·16 claims
- 0385US2025114449A1Stable anti-osmr antibody formulationKINIKSA PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 0483US11325979B2Treatment of cytokine release syndrome with GM-CSF antagonistsKINIKSA PHARMACEUTICALS LTD·Filed 2021·Granted May 10, 2022·2 cites·28 claims
- 0581US9663571B2Oncostatin M receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2014·Granted May 30, 2017·3 cites·16 claims
- 0678US12122837B2Oncostatin M receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2021·Granted Oct 22, 2024·0 cites·28 claims
- 0778US10421813B2Oncostatin M receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2017·Granted Sep 24, 2019·1 cites·12 claims
- 0878US2025236676A1TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODYKINIKSA PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 0977US9738721B1Oncostatin M receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2017·Granted Aug 22, 2017·1 cites·16 claims
- 1074US11141479B2Stable anti-OSMR antibody formulationKINIKSA PHARMACEUTICALS LTD·Filed 2019·Granted Oct 12, 2021·0 cites·19 claims
- 1174US2024101690A1TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRBeta ANTIBODYKINIKSA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 1273US2022062414A1Stable Anti-OSMR Antibody FormulationKINIKSA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 1371US2024117058A1Treatment of cytokine release syndrome with gm-csf antagonistsKINIKSA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 1468US10493149B2Stable anti-OSMR antibody formulationKINIKSA PHARMACEUTICALS LTD·Filed 2018·Granted Dec 3, 2019·0 cites·19 claims
- 1568US2019359724A1Oncostatin m receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
- 1667US10391170B2Stable anti-OSMR antibody formulationKINIKSA PHARMACEUTICALS LTD·Filed 2018·Granted Aug 27, 2019·0 cites·16 claims
- 1765US2021054085A1Treatment of skin diseases or disorders by delivery of anti-osmrb antibodyKINIKSA PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
- 1862US2023279135A1Pharmaceutical compositions of humanized anti-cd40 antibodiesKINIKSA PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 1959US2023287132A1Methods of treating or reducing risk of transplant rejectionKINIKSA PHARMACEUTICALS LTD·Filed 2023·Application pending·0 cites
- 2058US2021284744A1Treatment of cytokine release syndrome with gm-csf antagonistsKINIKSA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 2156US2023183367A1Pharmaceutical compositions of humanized anti-cd40 antibodies and uses thereofKINIKSA PHARMACEUTICALS LTD·Filed 2022·Application pending·0 cites
- 2251US2022281914A1Protein compositions and methods for producing and using the sameKINIKSA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 2345US2022184179A1Treatment of cancers with gm-csf antagonistsKINIKSA PHARMACEUTICALS LTD·Filed 2021·Application pending·0 cites
- 2438US2022331425A1Treatment of cancers with gm-csf antagonistsKINIKSA PHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when KINIKSA PHARMACEUTICALS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →